title: Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Shimizu
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Misu
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takahashi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Fujihara
authors.forename: Seiji
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Itoyama
authors.forename: Makoto
authors.initials: M
authors.lastname: Iwata
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D001927:Brain Diseases / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009187:Myelitis / Q000150:complications* / Q000188:drug therapy*; D009471:Neuromyelitis Optica / Q000150:complications* / Q000188:drug therapy*; D011994:Recombinant Proteins; D013116:Spinal Cord / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D001379:Azathioprine